SCHEMBL5746202

SCHEMBL5746202

CC1CN(c2ccc(OC(F)(F)F)cc2)CC(C)N1S(=O)(=O)c1ccc(O)c(CC(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.52
PTGDR2 Q9Y5Y4 5/20 0.41
HSD11B1 P28845 2/20 0.41
CHRM2 P08172 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM5 P08912 1/20 0.39
CHRM3 P20309 1/20 0.39
CHRM4 P08173 2/20 0.37
RORC P51449 1/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
PTGDR Q13258 1/20 0.37
AKR1C3 P42330 1/20 0.37
FFAR4 Q5NUL3 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5747676 0.92 PPARD (0.51) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5481306 0.91 PPARD (0.52) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5481305 0.91 PPARD (0.52) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5546066 0.86 PPARD (0.48) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5776063 0.85 PPARD (0.50) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL1470796 0.84 PPARD (0.48) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL1470799 0.84 PPARD (0.48) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL14431174 0.84 PPARD (0.57) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5482062 0.84 PPARD (0.57) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL14431186 0.84 PPARD (0.51) PPARDPTGDR2HSD11B1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD PPARD 3/4885PTGDR2 560/4885HSD11B1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.